The DOI matches its OpenAlex record; 70 of the 70 references it cites were found in a registry or an index.
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
Open accessAbstract
BACKGROUND: The biologic disease-modifying anti-rheumatic drugs (DMARDs) are very effective in treating rheumatoid arthritis (RA), however there is a lack of head-to-head comparison studies. OBJECTIVES: To compare the efficacy and safety of abatacept, adalimumab, anakinra, etanercept, infliximab, and rituximab in patients with RA. METHODS: This 'Overview of Reviews' was done by including all Cochrane Reviews on Biologics for RA available in The Cochrane Library. We included only data on standard dosing regimens for these biologic DMARDs from placebo-controlled trials. The primary efficacy and safety outcomes were ACR50 and withdrawals due to adverse events. We calculated Risk Ratios (RR) for efficacy, Odds Ratio (OR) for safety and combined estimates of events across the placebo groups as the expected Control Event Rate (CER). Indirect comparisons of biologics were performed for efficacy and safety using a hierarchical linear mixed model incorporating the most important study-level characteristic (i.e. type of biologic) as a fixed factor and study as a random factor; reducing the between study heterogeneity by adjusting for the interaction between the proportion of patients responding on placebo and the duration of the trial. MAIN RESULTS: From the six available Cochrane reviews, we obtained data from seven studies on abatacept, eight on adalimumab, five on anakinra, four on etanercept, four on infliximab, and three on rituximab.The indirect comparison estimates showed similar efficacy for the primary efficacy outcome for all biologics with three exceptions. Anakinra was less efficacious than etanercept with a ratio of RRs (95% CI; P value) of 0.44 (0.23 to 0.85; P = 0.014); anakinra was less efficacious than rituximab, 0.45 (0.22 to 0.90; P = 0.023); and likewise adalimumab was more efficacious than anakinra, 2.34 (1.32 to 4.13; P = 0.003).In terms of safety, adalimumab was more likely to lead to withdrawals compared to etanercept, with a ratio of ORs of 1.89 (1.18 to 3.04; P = 0.009); anakinra more likely than etanercept, 2.05 (1.27 to 3.29; P = 0.003); and likewise etanercept less likely than infliximab, 0.37 (0.19 to 0.70; P = 0.002). AUTHORS' CONCLUSIONS: Based upon indirect comparisons, anakinra seemed less efficacious than etanercept, adalimumab and rituximab and etanercept seemed to cause fewer withdrawals due to adverse events than adalimumab, anakinra and infliximab. Significant heterogeneity in characteristics of trial populations imply that these finding must be interpreted with caution. These findings can inform physicians and patients regarding their choice of biologic for treatment of RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,382
Development of AMSTAR: A measurement tool to assess the methodological quality of systematic reviews
Shea, B. J., Grimshaw, J. M., Wells, G. A., Boers, M., Andersson, N., Hamel, C., Porter, A. C., Tugwell, P., Moher, D., & Bouter, L. M. (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-10 · Cited by 4,374
Self-citationInfliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Self-citationBongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
Random-effects model for meta-analysis of clinical trials: An update
DerSimonian, R., & Kacker, R. (2007) · Contemporary Clinical Trials · doi:10.1016/j.cct.2006.04.004 · Cited by 2,374
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
Choy, E. H. S., & Panayi, G. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103223441207 · Cited by 2,249
Radiographic Evaluation of Rheumatoid Arthritis and Related Conditions by Standard Reference Films
Larsen, A., Dale, K., & Eek, M. (1977) · Acta Radiologica. Diagnosis · doi:10.1177/028418517701800415 · Cited by 1,825
Klareskog, L., van der Heijde, D., de Jager, J. P., Gough, A., Kalden, J., Malaise, M., Mola, E. M., Pavelka, K., Sany, J., Settas, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15640-7 · Cited by 1,751
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734
van Gestel, A. M., Prevoo, M. L. L., van't Hof, M. A., van Rijswijk, M. H., van de Putte, L. B. A., & van Riel, P. L. C. M. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390105 · Cited by 1,572
Pincus, T., Summey, J. A., Soraci, S. A., Wallston, K. A., & Hummon, N. P. (1983) · Arthritis & Rheumatism · doi:10.1002/art.1780261107 · Cited by 1,337
Lee, D. M., & Weinblatt, M. E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06075-5 · Cited by 1,247
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
Genovese, M. C., Becker, J.-C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050524 · Cited by 1,241
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,172
Evidence that cytokines play a role in rheumatoid arthritis
Brennan, F. M., & McInnes, I. B. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36389 · Cited by 1,103
Evaluation of networks of randomized trials
Salanti, G., Higgins, J. P., Ades, A., & Ioannidis, J. P. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207080643 · Cited by 1,078
Song, F., Altman, D. G., Glenny, A.-M., & Deeks, J. J. (2003) · BMJ · doi:10.1136/bmj.326.7387.472 · Cited by 943
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007) · Statistics in Medicine · doi:10.1002/sim.2528 · Cited by 938
The Disease Activity Score and the EULAR Response Criteria
Fransen, J., & van Riel, P. L. C. M. (2009) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2009.10.001 · Cited by 877
Development of a disease activity score based on judgment in clinical practice by rheumatologists.
van der Heijde, D. M. F. M., Hof, M. V. '., van Riel, P. L., & van de Putte, L. B. (1993) · PubMed · Cited by 787
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Van Der Heijde, D., Van Riel, P., Gribnau, F., Nuver-Zwart, I., & Van De Putte, L. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92442-2 · Cited by 556
Schiff, M., Keiserman, M., Codding, C., Songcharoen, S., Berman, A., Nayiager, S., Saldate, C., Li, T., Aranda, R., Becker, J.-C., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.080002 · Cited by 539
Sharp, J. T., Lidsky, M. D., Collins, L. C., & Moreland, J. (1971) · Arthritis & Rheumatism · doi:10.1002/art.1780140605 · Cited by 503
Finckh, A., Liang, M. H., van Herckenrode, C. M., & de Pablo, P. (2006) · Arthritis Care & Research · doi:10.1002/art.22353 · Cited by 492
(1993) · PubMed · Cited by 469
Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis
Scott, D. L., & Kingsley, G. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmct055183 · Cited by 461
Epidemiology and burden of illness of rheumatoid arthritis
Kvien, T. K. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422001-00002 · Cited by 435
Fleischmann, R. M., Schechtman, J., Bennett, R., Handel, M. L., Burmester, G., Tesser, J., Modafferi, D., Poulakos, J., & Sun, G. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10870 · Cited by 392
PREVOO, M. L. L., VAN GESTEL, A. M., VAN THOF, M. A., VAN RIJSWIJK, M. H., VAN DE PUTTE, L. B. A., & VAN RIEL, P. L. C. M. (1996) · Rheumatology · doi:10.1093/rheumatology/35.11.1101 · Cited by 373
Macrophages and their products in rheumatoid arthritis
Szekanecz, Z., & Koch, A. E. (2007) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32805e87ae · Cited by 308
Donahue, K. E., Gartlehner, G., Jonas, D. E., Lux, L. J., Thieda, P., Jonas, B. L., Hansen, R. A., Morgan, L. C., & Lohr, K. N. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-2-200801150-00192 · Cited by 299
Alonso-Ruiz, A., Pijoan, J. I., Ansuategui, E., Urkaregi, A., Calabozo, M., & Quintana, A. (2008) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-9-52 · Cited by 250
Gartlehner, G., Hansen, R. A., Jonas, B., Thieda, P., & Lohr, K. N. (2006) · PubMed · Cited by 238
Generic quality-of-life assessment in rheumatoid arthritis.
Tugwell, P., Idzerda, L., & Wells, G. A. (2007) · PubMed · Cited by 214
Self-citationAnakinra for rheumatoid arthritis
Mertens, M., & Singh, J. A. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005121.pub3 · Cited by 179
Self-citationT cells in rheumatoid arthritis
Cope, A. P. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2412 · Cited by 177
Second-Line Drug Therapy for Rheumatoid Arthritis
Wood, A. J. J., Cash, J. M., & Klippel, J. H. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301908 · Cited by 160
Nixon, R. M., Bansback, N. J., & Brennan, A. (2006) · Statistics in Medicine · doi:10.1002/sim.2624 · Cited by 156
Bongartz, T., Warren, F. C., Mines, D. I., Matteson, E. L., Abrams, K. R., & Sutton, A. J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.094904 · Cited by 155
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Burmester, G. R., Sieper, J., Emery, P., Keystone, E., Schiff, M., Mease, P. J., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.081430 · Cited by 153
Pincus, T. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/41.12.1346 · Cited by 151
Adalimumab for treating rheumatoid arthritis
Navarro-Sarabia, F., Ariza‐Ariza, R., Hernández‐Cruz, B., & Villanueva, I. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005113.pub2 · Cited by 140
Infliximab for the treatment of rheumatoid arthritis
Blumenauer, B. B., Judd, M., Wells, G. A., Burls, A., Cranney, A., Hochberg, M. C., Tugwell, P., & Lopez-Olivo, M. A. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003785 · Cited by 133
Self-citationThe Mast Cell in Inflammatory Arthritis
Woolley, D. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmcibr023206 · Cited by 132
Rituximab for rheumatoid arthritis
Lopez-Olivo, M. A., Amezaga, M., McGahan, L., Pollono, E. N., & Suarez-Almazor, M. E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007356.pub2 · Cited by 125
Self-citationPatient-reported outcomes and their role in the assessment of rheumatoid arthritis
Lubeck, D. P. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422001-00004 · Cited by 123
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008
Fürst, D. E., Keystone, E. C., Kirkham, B., Fleischmann, R., Mease, P. J., Fc, B., Smolen, J. S., Kalden, J. R., Burmester, G. R., Braun, J., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.100834 · Cited by 114
Abatacept for rheumatoid arthritis
Maxwell, L. J., & Singh, J. A. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007277.pub2 · Cited by 108
Self-citationØdegård, S., Finset, A., Kvien, T. K., Mowinckel, P., & Uhlig, T. (2005) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740510018633 · Cited by 106
Barlow, J., Cullen, L., & Rowe, I. F. (1999) · Patient Education and Counseling · doi:10.1016/s0738-3991(98)00144-x · Cited by 83
Etanercept for the treatment of rheumatoid arthritis
Blumenauer, B. B., Cranney, A., Burls, A., Coyle, D., Hochberg, M. C., Tugwell, P., & Wells, G. A. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004525 · Cited by 80
Self-citationGeneralized linear mixed models for meta-analysis
Platt, R. W., Leroux, B. G., & Breslow, N. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<643::aid-sim76>3.0.co;2-m · Cited by 74
Work disability in rheumatic diseases
Yelin, E. H. (2007) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3280126b66 · Cited by 71
Etanercept for the treatment of rheumatoid arthritis
Lethaby, A. E., Lopez-Olivo, M. A., Maxwell, L. J., et al. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004525.pub2 · Cited by 70
Self-citationKristensen, L. E., Christensen, R., Bliddal, H., Geborek, P., Danneskiold‐Samsøe, B., & Saxne, T. (2007) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740701607067 · Cited by 67
Self-citationNumber needed to treat (NNT): implication in rheumatology clinical practice
Osiri, M., Suarez-Almazor, M. E., Wells, G. A., Robinson, V., & Tugwell, P. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.4.316 · Cited by 63
Self-citationNew cytokine targets in inflammatory rheumatic diseases
Connell, L. E., & McInnes, I. B. (2006) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2006.05.011 · Cited by 59
Lee, Y. H., Woo, J. H., Rho, Y. H., et al. (2007) · Rheumatology International · doi:10.1007/s00296-007-0475-6 · Cited by 54
Boers, M. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70209-x · Cited by 48
Chung, C. P., Thompson, J. L., Koch, G. G., Amara, I. A., Strand, V., & Pincus, T. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.048975 · Cited by 48
Anakinra for rheumatoid arthritis
Mertens, M. T., & Singh, J. A. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005121.pub2 · Cited by 47
Self-citationAbatacept for rheumatoid arthritis
Maxwell, L. J., & Singh, J. A. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007277 · Cited by 24
Self-citationExplaining heterogeneity in meta-analysis: a comparison of methods
Thompson, S. G., & Sharp, S. J. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19991030)18:20
Cited by
Singh, J. A., Furst, D. E., Bharat, A., Curtis, J. R., Kavanaugh, A. F., Kremer, J. M., Moreland, L. W., O'Dell, J., Winthrop, K. L., Beukelman, T., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21641 · Cited by 1,789
Self-citationMethodology in conducting a systematic review of systematic reviews of healthcare interventions
Smith, V., Devane, D., Begley, C. M., & Clarke, M. (2011) · BMC Medical Research Methodology · doi:10.1186/1471-2288-11-15 · Cited by 1,227
Adverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
Self-citationSingh, J. A., Cameron, C., Noorbaloochi, S., Cullis, T., Tucker, M., Christensen, R., Ghogomu, E. T., Coyle, D., Clifford, T., Tugwell, P., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61704-9 · Cited by 623
Self-citationBlockade of TNF-α rapidly inhibits pain responses in the central nervous system
Hess, A., Axmann, R., Rech, J., Finzel, S., Heindl, C., Kreitz, S., Sergeeva, M., Saake, M., Garcia, M., Kollias, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011774108 · Cited by 356
Metadata
- Authors
- Singh, J. A., Christensen, R., Wells, G. A., Suarez-Almazor, M. E., Buchbinder, R., Lopez-Olivo, M. A., Ghogomu, E. T., & Tugwell, P.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Elsevier BV
- Published
- 2009-10-07
- Issue
- 4
- Pages
- CD007848-CD007848
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W1550247426
- Cited by
- 470
- References
- 70
- Type
- reference entry
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.